5Boulos Haraoui, Marilyn Krelenbaum, Emergence of Crohn's Disease During Treatment with the Anti - Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis : Possible Mechanisms of Action [J].Seminars in Arthritis and Rheumatism,In Press,Corrected Proof, Available online at www. sciencedirect, com ,2008,8,15
8Haibel H, Rudwaleit M, Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis [ J ]. Ann Rheum Dis, 2005, 64(1) :124
4Kahn MA, van der Linden. Ankylosing spondylitis and other spondy-loarthropathies[J]. Rheum Dis Clin North Am ,1990,16(3):551.
5Blanco FJ, Guitian R, Moreno J, et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondroeytes[ J ]. J Rheumatol, 1999,26 : 1366 - 1373.
6Gran JT, Husby G. Ankylosing spondylitis: Current drug treatment[J ]. Drugs, 1992,44(4) :585 - 603.
7Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15rng in subjects with rheumatic disease and mild renal impairment[J]. Br J Rheumatol,1996,35(Suppl 1) :S56 - S60.
8Dougados M,Gueguen A, Nakache JP, et al. Ankylosing spondytitis: what is the optimtma duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial[J]. Rheumatology(Oxford), 1999,38(3) :235 - 244.
9Davis J, Huang F, Maksy mowych W P. New therapies for ankylosing spondylitis: etanercept, thalidomide and pamidronate.Rheum Dis Clin North Am, 2003,29:501
10Huang F, Gu J, Zhao W, et al. one-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (Arthritis Care Res), 2002,47:249
